
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
How Lytenava's FDA approval will impact clinical treatment of nAMD
2
Instilling safe contact lens wearing practices in patients
3
Perceived stress may precede worsening dry eye symptoms in young adults, study finds
4
A primer on oral omega-3s and dry eye disease
5


















